Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | RARB | P10826 | 4/20 | 0.43 |
| ▸ | RARG | P13631 | 4/20 | 0.43 |
| ▸ | RARA | P10276 | 3/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.40 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659590 | 1.00 | NOTUM (0.44) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL5656270 | 0.89 | NOTUM (0.43) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL12604316 | 0.86 | NOTUM (0.47) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL10408115 | 0.84 | RARA (0.47) | RARBRARGRARAPTGS1PTGS2 | |
| SCHEMBL24673929 | 0.83 | NOTUM (0.44) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL5656267 | 0.83 | PTGS1 (0.42) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL987763 | 0.80 | RARB (0.41) | NOTUMRARBRARGRARAPTGS1 | |
| SCHEMBL30134196 | 0.75 | PTGS1 (0.40) | PTGS1PTGS2UGT2B7AOC3 | |
| SCHEMBL30134081 | 0.75 | PTGS1 (0.40) | PTGS1PTGS2UGT2B7AOC3 | |
| SCHEMBL8982307 | 0.75 | NOTUM (0.49) | NOTUMRARBRARGRARAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | NOTUM 3448/4885RARB 325/4885RARG 326/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | NOTUM 3280/4885RARB 564/4885RARG 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.